ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
THE WOODLANDS, Texas, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the United States Court of Appeals for the Federal Circuit summarily affirmed the ruling of the United States District Court for the Southern District of Texas in favor of the Company in the Company’s motions for summary judgment that Dr. Fisch failed to present sufficient evidence to be added as a co-inventor of U.S. Patent Nos. 7,737,185 and 7,759,360, covering therapeutic uses of enclomiphene, and that equitable estoppel barred Dr. Fisch's counterclaims seeking to be added as a co-inventor of the patents at issue, in its lawsuit against Dr. Harry Fisch.
About Repros Therapeutics Inc.®
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
For more information, please visit the Company’s website at http://www.reprosrx.com.
CONTACT: Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931 [email protected]
